Blandt diabetiske, hypertensive patienter med kronisk nyreinsufficiens og udtalt proteinuri sås hyperkalæmi (≥5, 5 mEq/ l) hos 46, 3% af patienterne i irbesartangruppen og 26, 3% af patienterne i placebogruppen.
In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/ L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.